Tubular Markers in Response to Saxagliptin Therapy

Summary

the study aims to investigate whether treatment with saxagliptin would induce beneficial changes in renal NGAL and L-FABP biomarkers and if they would be used as a tool to identify patients' categories with a particular renal response to DPP-4inhibition. Secondly, to find an association between NGAL and L-FABP, and the relevant renal parameters for both baseline values and rate of changes across defined time points.

Timeline

Start

2019-03-01

Primary completion

2020-03-01

Completion

2020-04-01

Drugs

Indications